Efficacy and safety of peanut epicutaneous immunotherapy in patients with atopic comorbidities.
Epicutaneous immunotherapy
Viaskin Peanut
children
concomitant atopic conditions
desensitization
food allergy
immunotherapy
peanut allergy
Journal
The journal of allergy and clinical immunology. Global
ISSN: 2772-8293
Titre abrégé: J Allergy Clin Immunol Glob
Pays: United States
ID NLM: 9918453488706676
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
10
03
2022
revised:
11
07
2022
accepted:
18
07
2022
medline:
2
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Co-occurring atopic conditions are common in children with peanut allergy. As such, it is important to examine the safety and efficacy of epicutaneous immunotherapy with Viaskin Peanut 250 μg patch (VP250) in peanut-allergic children with these conditions. We sought to compare efficacy and safety of VP250 versus placebo in peanut-allergic children with/without ongoing atopic conditions at baseline, including asthma, atopic dermatitis/eczema, or concomitant food allergy. A subgroup analysis of peanut-allergic children aged 4 to 11 years enrolled in PEPITES (12 months) and REALISE (6 months) randomized, placebo-controlled, phase 3 trials was conducted. The efficacy outcome measure was the difference in prespecified responder rate between placebo and VP250 groups at month 12 based on eliciting dose of peanut protein using double-blind, placebo-controlled food challenge in PEPITES. Safety profiles were evaluated by baseline concomitant disease subgroup in all randomized subjects who received 1 or more dose of the study drug in PEPITES and REALISE pooled data. Responder rates were significantly ( The results support the safety and efficacy of VP250 for treating peanut-allergic children with or without concomitant atopic conditions.
Sections du résumé
Background
UNASSIGNED
Co-occurring atopic conditions are common in children with peanut allergy. As such, it is important to examine the safety and efficacy of epicutaneous immunotherapy with Viaskin Peanut 250 μg patch (VP250) in peanut-allergic children with these conditions.
Objective
UNASSIGNED
We sought to compare efficacy and safety of VP250 versus placebo in peanut-allergic children with/without ongoing atopic conditions at baseline, including asthma, atopic dermatitis/eczema, or concomitant food allergy.
Methods
UNASSIGNED
A subgroup analysis of peanut-allergic children aged 4 to 11 years enrolled in PEPITES (12 months) and REALISE (6 months) randomized, placebo-controlled, phase 3 trials was conducted. The efficacy outcome measure was the difference in prespecified responder rate between placebo and VP250 groups at month 12 based on eliciting dose of peanut protein using double-blind, placebo-controlled food challenge in PEPITES. Safety profiles were evaluated by baseline concomitant disease subgroup in all randomized subjects who received 1 or more dose of the study drug in PEPITES and REALISE pooled data.
Results
UNASSIGNED
Responder rates were significantly (
Conclusions
UNASSIGNED
The results support the safety and efficacy of VP250 for treating peanut-allergic children with or without concomitant atopic conditions.
Identifiants
pubmed: 37780103
doi: 10.1016/j.jacig.2022.07.009
pii: S2772-8293(22)00071-6
pmc: PMC10509968
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69-75Informations de copyright
© 2022 The Authors.
Références
JAMA. 2019 Mar 12;321(10):946-955
pubmed: 30794314
J Allergy Clin Immunol. 2017 Apr;139(4):1242-1252.e9
pubmed: 28091362
JAMA. 2017 Nov 14;318(18):1798-1809
pubmed: 29136445
Am J Manag Care. 2018 Oct;24(19 Suppl):S419-S427
pubmed: 30427645
Allergy Asthma Proc. 2020 Sep 1;41(5):326-335
pubmed: 32539908
J Allergy Clin Immunol. 2014 Nov;134(5):1016-25.e43
pubmed: 25174862
Pediatrics. 2018 Dec;142(6):
pubmed: 30455345
Expert Rev Clin Immunol. 2019 Dec;15(12):1333-1339
pubmed: 31774311
Dermatology. 1997;195(1):10-9
pubmed: 9267730
J Allergy Clin Immunol Pract. 2022 Jul;10(7):1864-1873.e10
pubmed: 34848381
J Pediatr. 2018 Jan;192:223-228.e1
pubmed: 29246346
J Immunol. 2011 May 15;186(10):5629-37
pubmed: 21490160
J Allergy Clin Immunol. 2020 Oct;146(4):863-874
pubmed: 32659313